Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Interest & Investment Income (2017 - 2025)

United Therapeutics' Interest & Investment Income history spans 15 years, with the latest figure at $43.2 million for Q4 2025.

  • For Q4 2025, Interest & Investment Income fell 12.37% year-over-year to $43.2 million; the TTM value through Dec 2025 reached $192.0 million, down 3.57%, while the annual FY2025 figure was $192.0 million, 3.57% down from the prior year.
  • Interest & Investment Income for Q4 2025 was $43.2 million at United Therapeutics, down from $46.4 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $53.8 million in Q1 2024 and bottomed at $3.8 million in Q3 2021.
  • The 5-year median for Interest & Investment Income is $40.2 million (2023), against an average of $30.8 million.
  • The largest annual shift saw Interest & Investment Income tumbled 53.0% in 2021 before it skyrocketed 579.07% in 2023.
  • A 5-year view of Interest & Investment Income shows it stood at $4.2 million in 2021, then skyrocketed by 395.24% to $20.8 million in 2022, then soared by 145.19% to $51.0 million in 2023, then decreased by 3.33% to $49.3 million in 2024, then fell by 12.37% to $43.2 million in 2025.
  • Per Business Quant, the three most recent readings for UTHR's Interest & Investment Income are $43.2 million (Q4 2025), $46.4 million (Q3 2025), and $51.3 million (Q2 2025).